EACS2023: 412 Acceptability and health-related quality of life among HIV patients switching to a dual therapy with DTG/3TC: results from PROBI study M. Duracinsky , T. Alain , O. Rousset Torrente , L. Hocqueloux , N. Hall , O. Zaegel-Faucher , C. Allavena , D. Zucman , O. Chassany Health Economics Clinical Trial Unit (URC-ECO), Patient-Reported Outcomes Research (PROQOL), Paris, France, Paris Cité University, Inserm, ECEVE, UMR-S 1123, Paris, France, Regional Hospital Center of Orléans, Department of internal medicine, Orléans, France, Quimper Hospital, Public Health Centre, Quimper, France, Assistance Publique-Hôpitaux de Marseille, Marseille, France, INSERM EA 1413, Infectious Diseases Department, CHU Nantes, Nantes, France, Foch Hospital, Department of Internal Medicine, Suresnes, France General data Abstract category: Antiretroviral therapy – observational studies Abstract body Purpose: In an era of high efficacy of ART regimens, Patient-Reported outcomes (PROs) are important endpoints. The PROBI study is a French, real-life single arm study to evaluate PROs of patients with virologically suppressed HIV (PWH) switching to a dual therapy with DTG/3TC. Method: Data were collected at baseline (M0), 1, and 6 months (M1, M6). Overall Treatment Evaluation (OTE), HIV Index Symptom (HIS) and Health Related Quality of Life (HRQOL) with PROQOL-HIV and Acceptability Dimension were self assessed. Paired t-test was used for significance differences. Results: From April 2021 to May 2023, 261 patients participated in 25 centers, with a mean age of 51 years (±12) of whom 64% were men, and 1% transgender. At baseline mean CD4 was 738±408 cells/mm3, 99% had an undetectable viral load under 50 copies/mL. 20 patients stopped DTG/3TC, with reasons reported: 9 neuropsychiatric disorders, 6 digestive disorders, 4 osteoarticular disorders, 3 weight gain, 2 travel-related adherence problems, 5 on-patient demand, and 4 other reasons. No virologic failure was observed under DTG/3TC regimen. Among patients who continued DTG/3TC with no missing questionnaire (n=217), OTE improved by 0.55±1.14 (scale ranging -4/+4) at M6. From M0 to M6, and HIS mean score (0-100) remained stable with -2 points (95%CI, -4.7 – 0.11, p=0.061). PROQOL-HIV dimension: Acceptability scale mean score (0-100) increased by 6.2 points (95%CI, 2.6-9.8, p<0.001), Cognitive and mental dimension mean scores (0-100) increased of 4.7 points (95%CI, 1.0-8.3, p=0.013) and Treatment impact dimension mean score (0-100) increased of 5.4 points (95%CI, 3.0-7.8, p<0.001). Conclusions: Several PRO scores improved following the switch to DGT/3TC, with better treatment acceptability and a positive impact on HRQOL. General conditions 1. I confirm that I previewed this abstract and that all information is correct. I accept that the content of this abstract cannot be modified or corrected after the submission deadline and I am aware that it will be published exactly as submitted.: Yes 2. I confirm that the submission of the abstract constitutes my consent to publication (e.g. conference website, programmes, other promotions, etc.). : Yes 3. I herewith confirm that the contact details saved in this system are those of the corresponding author, who will be notified about the status of the abstract. The corresponding author is responsible for informing the other authors about the status of the abstract.: Yes 4. I agree that all data provided may be used (saved, stored, processed, transmitted and deleted) in compliance with the privacy policy to provide the services described.: Yes 1,2 1 1,2 3 4 5 6 7 1,2 1 2 3 4 5 6 7 117
RkJQdWJsaXNoZXIy Mzc2ODc=